Episode # 177 • 09 Jul 2024
Latest Approaches to Treat High-Risk NMIBC
Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena.
This podcast is supported by
Timestamps
00:00 - Introduction
03:56 - Initial Diagnosis and Workup
12:22 - High-Grade Bladder Cancer
22:37 - BCG and Alternative Treatments
31:30 - BCG Unresponsive Disease
36:56 - Novel Intravesical and Systemic Therapies
46:45 - Future Directions
Resources
You may also like
More about this episode
Dr. Kamat explores the evolving role of BCG and potential alternative therapies such as gemcitabine and docetaxel. He also covers effective clinical management, emerging clinical trials, and nuanced decision-making principles for radical cystectomy. Finally, the conversation touches on Dr. Kamat’s expert insights regarding the future of NMIBC management, including predictive biomarkers and personalized medicine.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.